SAN FRANCISCO, Nov. 10, 2021 /PRNewswire/ -- The global investigational new drug CDMO market size is expected to reach USD 6.8 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 6.9% from 2021 to 2028. This is largely due to the increased R&D investments, along with stringent regulations pertaining to IND.
Key Insights & Findings:
In terms of product, the small molecule segment dominated the market with a revenue share of 89.0% in 2020. This is largely due to the increasing number of small molecules in development. Besides, in 2019, the small molecules dominated the new drug approvals accounting for 79% of all the NME approvals
Based on service, the contract development segment led the market with a revenue share of 85.5% in 2020. The contract development offers several benefits over in-house development of drugs, such as access to industry experts, less time to market, cost-effectiveness, and more focus on core competencies
By end user, pharmaceutical companies accounted for the largest share of 69.4% in 2020. This is due to the changes in the pharmaceutical industry that have an impact on research and development strategies, which, in turn, influence new drug approval trends
Asia Pacific to register the fastest growth rate of 7.7% over the forecast period. Due to the rapid growth of pharmaceutical firms and contract manufacturing organizations in developing countries, such as India and China, the region is likely to overtake Europe and North America in the near future
The U.S. FDA and the European Medicines Agency (EMA) are health authority bodies that regulate the use of investigational drugs in the U.S. and the European Union, respectively. In addition, investigational review boards (IRBs) in the U.S. and ethics committees (ECs) in the European Union must approve the use of drugs in humans.
It is the requirement of a federal law that a drug be the subject of an approved marketing application prior to it is distributed or transported across the state lines. Hence, sponsors aiming to conduct clinical studies that involve an IND should gain exemption from the FDA to permit the shipping of the investigational drug to clinical investigators in several states.
The pandemic has significantly impacted the global economy in 2020 and has an ongoing impact on various industries. However, the market for IND CDMO has benefited from the pandemic. Prior to COVID-19, prospective sponsors demanded facility audits to ensure CDMOs had the required capacity, equipment, and personnel to undertake their projects. Nowadays, CDMOs should find new ways to attract new sponsors, such as through videos, virtual reality, and other technologies that allow sponsors to virtually experience the site.
Grand View Research has segmented the global investigational new drug CDMO market based on product, service, end user, and region:
IND CDMO Product Outlook (Revenue, USD Million, 2016 - 2028)
IND CDMO Service Outlook (Revenue, USD Million, 2016 - 2028)
Bioanalysis and DMPK Studies
Pathology and Safety Pharmacology Studies
Drug Substance Synthetic Route Development
Drug Substance Process Development
Form Selection Crystallization Process Development
Scale-up of Drug Substance
Preclinical Formulation Selection
First In Man Formulation/ Process Development
Analytical Method Development / Validation
Release Testing of Drug Substance and Drug Product
Work Up Purification Steps
Telescoping & Process Refining
Formal Stability of Drug Substance and Drug Product
Cell Line Development
Liquid and Semi-solids
IND CDMO End-user Outlook (Revenue, USD Million, 2016 - 2028)
Others (Government, Research Institutes, Academic Institutes, etc.)
IND CDMO Regional Outlook (Revenue, USD Million, 2016 - 2028)
Middle East & Africa
List of Key Players of Investigational New Drug (IND) CDMO Market
Siegfried Holding AG
Thermo Fisher Scientific Inc.
Charles River laboratories Inc.
IQVIA Holdings Inc.
Check out more studies related to contract development and manufacturing organizations, conducted by Grand View Research:
Active Pharmaceutical Ingredients CDMO Market – The global active pharmaceutical ingredients CDMO market size was estimated at USD 81.6 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 6.7% from 2021 to 2028. The growth can be attributed to factors such as increased drug R&D, the rising incidence of chronic diseases, the expanding importance of generics, and the increasing consumption of biopharmaceuticals.
Healthcare Contract Development And Manufacturing Organization Market – The global healthcare contract development and manufacturing organization market size was valued at USD 204.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 8.6% from 2021 to 2028. An increase in uptake of outsourcing services by pharmaceutical companies and growth in R&D investments are expected to drive the market.
CDMO Market Procurement Intelligence Report – The global contract development manufacturing organization market is expected to witness sustainable growth (CAGR of 7.3%) from 2020 to 2025 with innovative APIs driving market growth. The COVID pandemic has had several positive as well as negative impacts on the industry.
Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.